Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from January 28 to February 10, 2026. At the end of the inspection, a ‘Form 483’ was issued with a total of 9 observations. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is now closed.
The above information is a part of company’s filings submitted to BSE.
